On November 21, 2019, pursuant to the terms and conditions of an Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), by and among Glaukos Corporation, a Delaware corporation (“Glaukos”), Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Glaukos (“Merger Sub”) and Avedro, Inc., a Delaware corporation (“Avedro”), Merger Sub was merged with and into Avedro, with Avedro continuing as the surviving corporation and a wholly owned subsidiary of Glaukos (the “Merger”). In accordance with the terms of the Merger Agreement, at the Effective Time the directors of Merger Sub immediately prior to the Effective Time, consisting of Thomas W. Burns and Joseph E. Gilliam, became the directors of the surviving corporation until their successors are duly elected or appointed and qualified, or until their earlier death, resignation or removal. Each of the directors of Avedro immediately prior to the Effective Time, consisting of Donald J. Zurbay, Honbgo Lu, Ph.D., Reza Zadno, Ph.D., Jonathan Silverstein, Garheng Kong, MD, Ph.D., and Robert J. Palmisano, voluntarily resigned and ceased serving as directors of Avedro as of the Effective Time.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a âsingle dose pharmaceutical,â sold primarily in conjunction with the Companyâs innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
AVEDRO, INC. 
